Tag: frequent bites of the apple

Michael Kors to Buy Versace – 3 Lessons for Acquirers

Michael Kors will purchase Versace for $2.1 billion as part of a plan to build a luxury fashion empire. After the deal closes, Michael Kors will change its name to Capri Holdings and have 18,000 employees worldwide. While you may (or may not) be a fashionista, here are three lessons any strategic acquirer can learn …

Continue reading

Nestle Slims Down, Sells US Chocolate Business – 3 Lessons for You

Nestle is selling its US chocolate business, which includes brands such as BabyRuth, Butterfinger, and Crunch to Ferrero for $2.8 billion. The deal is part of Nestle’s strategy to sell underperforming brands and refocus on healthier products and fast-growing markets. Nestle recently acquired vitamin maker Altrium Innovations for $2.3 billion and is rumored to be …

Continue reading

Acheiving Your Goal with Multiple Acquisitions

One of the most effective ways for strategic buyers to grow through acquisitions is to “take frequent small bites of the apple,” or to conduct a series of smaller, strategic acquisitions in order to achieve a growth goal. Even those these deals might not be as “exciting” as mergers between two huge competitors, they can …

Continue reading

4 Reasons Why Focusing on Small Acquisitions is Best

In light of recent FTC rulings against market domination, Sysco has changed its M&A strategy to focus on smaller, strategic deals rather than large transformative deals. Although Sysco’s change is motivated by regulatory obstacles to larger acquisitions, using strategic, smaller deals is an excellent approach from a strategic perspective. We have long recommended that our …

Continue reading

Endo Grows Generic Drug Business with Par Pharma Acquisition

On May 18, Endo announced it would acquire Par Pharmaceutical for $6.5 billion cash and $1.5 billion stock. The acquisition is the latest consolidation in a robust M&A market, especially in the healthcare sector. Endo has stated multiple reasons for the deal, including building its generic drug platform as well as significant operational and tax …

Continue reading